<DOC>
<DOCNO>EP-0647136</DOCNO> 
<TEXT>
<INVENTION-TITLE>
USE OF CONDENSED BIS-(3,4-DIHYDRO-PYRIDINYL)METHANE FOR TREATING CROHN'S DISEASE, COLITIS ULCEROSA, CHRONIC INFLAMATORY PROCESSES AND AS AN ANTIPROLIFERATIVE
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3147	C07D22100	A61P100	C07D51900	A61K31435	A61P2900	C07D21712	A61K3144	A61K31472	A61K3144	A61K31435	A61K3147	C07D22120	A61P2900	A61P100	C07D21700	A61K31472	C07D51900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	A61P	C07D	A61K	A61P	C07D	A61K	A61K	A61K	A61K	A61K	C07D	A61P	A61P	C07D	A61K	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D221	A61P1	C07D519	A61K31	A61P29	C07D217	A61K31	A61K31	A61K31	A61K31	A61K31	C07D221	A61P29	A61P1	C07D217	A61K31	C07D519	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Benzo- and thieno-3,4-dihydropyridine derivates having general formula (I), in which D stands for a group having formula (Ia), A and B standing for a benzo- or thieno residue, R2, R3, R5, R6, R7, R11, R12, m and n being as defined in the description, and their pharmaceutically tolerable salts, are used for preparing agents for treating chronic inflammatory processes, colitis ulcerosa and Crohn's disease, and antiproliferative agents.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM INT
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM KG
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM KG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ARNDTS DIETRICH
</INVENTOR-NAME>
<INVENTOR-NAME>
LOESEL WALTER
</INVENTOR-NAME>
<INVENTOR-NAME>
ROOS OTTO
</INVENTOR-NAME>
<INVENTOR-NAME>
ARNDTS, DIETRICH
</INVENTOR-NAME>
<INVENTOR-NAME>
LOESEL, WALTER
</INVENTOR-NAME>
<INVENTOR-NAME>
ROOS, OTTO
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a compound of general formula I 

 
wherein 


A denotes a benzo- or thieno- group; 
R
2
 and R
3
 independently of each other denote hydrogen or 
(C
1-5
)alkyl or, together with the carbon atom to which 
they are bound, a 5- or 6-membered carbocyclic group; 
R
11
 denotes (C
1-4
)alkyl, halogen (F, Cl, Br, I), hydroxy, 
(C
1-4
)alkoxy, amino, thiomethyl, methanesulphonyloxy or 
methanesulphonamido, or two adjacent R
11
 substituents 
together denote -O-CH
2
-O- or -O-CH
2
-CH
2
-O-; 
m denotes 0, 1, 2 or 3, if A is a benzo group, and 0, 1 
or 2, if A is a thieno group; 
and D denotes a group of formula Ia 

  
 

whilst in the group of formula Ia 
B denotes a benzo- or thieno- group; 
R
1
 denotes hydrogen, (C
1-10
)alkyl, phenyl, 
phenyl (C
1-5
) alkyl, (C
1-4
) alkoxy or -NHCOX (wherein X is 
(C
1-5
)alkyl); 
R
5
 denotes hydrogen, (C
1-4
)alkyl or hydroxymethyl; 
R
6
 and R
7
 independently of each other denote hydrogen or 
(C
1-5
)alkyl or together with the carbon atom to which 
they are bound denote a 5- or 6-membered carbocyclic 

group; 
R
12
 denotes (C
1-4
)alkyl, halogen (F, Cl, Br, I), hydroxy, 
(C
1-4
)alkoxy, amino, thiomethyl, methanesulphonyloxy or 
methanesulphonamido, or two adjacent R
12
 substituents 
together denote -O-CH
2
-O- or -O-CH
2
-CH
2
-O-; 
and n denotes 0, 1, 2 or 3 if B is a benzo group and 0, 
1 or 2 if B is a thieno group;
 
or the pharmaceutically acceptable salt thereof with an 

inorganic or organic acid for the preparation of a 
pharmaceutical composition for treating chronic 

inflammatory processes, ulcerative colitis and Crohn's 
disease and for producing a pharmaceutical composition 

having an antiproliferative effect. 
Use of a compound according to claim 1, wherein 

R
1
 denotes hydrogen, (C
1-10
)alkyl, phenyl(C
1-5
)alkyl 
or -NHCOX (wherein X is (C
1-5
)alkyl); 
R
11
 and R
12
 independently of each other denote 
(C
1-4
)alkyl, hydroxy, (C
1-4
)alkoxy, 
methanesulphonyloxy or methanesulphonamido, or two  

 
adjacent R
11
 and R
12
 substituents together denote 
-O-CH
2
-O- or -O-CH
2
-CH
2
-O-;
 
wherein preferably R
1
 denotes hydrogen, (C
1-10
)alkyl 
or -NHCOX (wherein X is (C
1-5
)alkyl); 
R
2
, R
3
, R
6
 and R
7
 independently of one another 
denote hydrogen or R
2
 together with R
3
 and/or R
6
 
together with R
7
 and the associated carbon atom to 
which they are bound denote a 5- or 6-membered 

carbocyclic group; 
R
11
 and R
12
 independently of each other denote 
hydroxy, (C
1-4
)alkoxy, methanesulphonyloxy or 
methanesulphonamido, or two adjacent R
11
 and R
12
 
substituents together denote -O-CH
2
-O- or 
-O-CH
2
-CH
2
-O-;
 
wherein in particular R
1
 denotes hydrogen, 
(C
1-6
)alkyl or -NHCOCH
3
 and/or 
R
5
 denotes hydrogen, methyl or hydroxymethyl and/or 
R
2
, R
3
, R
6
 and R
7
 independently of one another 
denote hydrogen or R
2
 together with R
3
 and/or R
6
 
together with R
7
 and the associated carbon atom to 
which they are bound denote a 5-membered 

carbocyclic group and/or 
R
11
 and R
12
 independently of each other denote 
hydroxy, methoxy, methanesulphonyloxy or 

methanesulphonamido, or two adjacent R
11
 and R
12
 
substituents together represent -O-CH
2
-O-. 
Use of a compound according to claim 1 or 2, 
wherein R
1
 and R
5
 denote hydrogen.  
 
Use of a compound according to one of claims 1 to 
3, wherein R
2
, R
3
, R
6
 and R
7
 denote hydrogen. 
Use of a compound according to one of claims 1 to 
3, wherein R
2
 and R
3
 or R
6
 and R
7
 together represent 
-(CH
2
)
4
-. 
Use of a compound according to one of claims 1 to 
5, wherein A and B independently of each other denote a 

thieno group, preferably 2,3-thieno. 
Use of a compound according to claim 6, wherein A 
and B denote an unsubstituted thieno group. 
Use of a compound according to one of claims 1 to 
5, wherein A and/or B is a benzo group, wherein m or n 

denotes 2. 
Use of a compound according to claim 8, wherein, if 
A and/or B is a benzo group, the two substituents R
11
 
and/or R
12
 in the benzo group are in the meta- or para-position, 
respectively, to the fusion points of the 

group A or B. 
Use of a compound according to one of claims 1 to 
5, 8 and 9, wherein R
11
 and R
12
 independently of each 
other denote hydroxy, (C
1-4
)alkoxy (preferably methoxy) 
or the 2 adjacent R
11
 and R
12
 substituents together 
denote -O-CH
2
-O-. 
Use of a compound according to claim 1 which is  
 


 
or a physiologically acceptable salt thereof. 
</CLAIMS>
</TEXT>
</DOC>
